



MEDTECS INTERNATIONAL CORPORATION LIMITED
(Incorporated in Bermuda)

MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

1. INTRODUCTION

The Board of Directors (the "**Board**") of Medtecs International Corporation Limited (the "**Company**", and together with its subsidiaries, the "**Group**") refers to the Company's announcements dated 3 December 2024, 27 December 2024, 17 January 2025, 24 January 2025, 27 February 2025, 27 March 2025, 25 April 2025, 8 May 2025, 28 May 2025, 30 June 2025, 25 July 2025, 25 August 2025, 24 September 2025, 29 October 2025, 24 November 2025, 29 December 2025, and 29 January 2026 (the "**Announcements**") in relation to, among others, the Winding Up Application and the Court Order in respect of Resilient Medical.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the meanings ascribed to them in the Announcements.

2. MONTHLY UPDATE PURSUANT TO CATALIST RULE 704(22)

Pursuant to Rule 704(22) of the Catalist Rules, the Board wishes to update shareholders that following the hearing held on 3 February 2026, the High Court of Singapore has granted an order that Resilient Medical be dissolved with effect from 3 February 2026.

Based on the liquidator's confirmation, the dissolution order marks the conclusion of the liquidation process, and all requisite steps under the liquidation have been completed.

Accordingly, no further action is required to be taken by the Company in relation to the liquidation, and no further monthly updates pursuant to Rule 704(22) are expected in this regard.

3. FINANCIAL IMPACT

Based on the information currently available to it, the Board has assessed that the dissolution of Resilient Medical pursuant to the court order does not have a material impact on the net tangible assets per share or the earnings per share of the Company for the financial year ending 31 December 2026.

4. CAUTION IN TRADING

Shareholders and potential investors of the Company are advised to read this announcement carefully. Shareholders and potential investors of the Company are advised to refrain from taking any action with respect to their securities in the Company which may be prejudicial to their interests, and to exercise caution when dealing in the securities of the Company. Shareholders and potential investors of the Company should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

BY ORDER OF THE BOARD

Clement Yang Ker-Cheng
Chairman – Executive Director
11 February 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.